0RIM Stock Chart & Stats
€0.08
>-€0.01(-1.42%)
At close: 4:00 PM EST
€0.08
>-€0.01(-1.42%)
Day’s Range― - ―
52-Week Range€0.08 - €0.24
Previous CloseN/A
Volume100.00
Average Volume (3M)122.44K
Market Cap
€19.64M
Enterprise Value€29.15M
Total Cash (Recent Filing)€1.67M
Total Debt (Recent Filing)€12.84M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Mar 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding235,044,330
10 Day Avg. Volume115,793
30 Day Avg. Volume122,445
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.62
Price to Sales (P/S)15482.52
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.08Price Target Upside0.00%
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.22
Revenue Forecast (FY)€11.20M
Bulls Say, Bears Say
Bulls Say
Debt ReductionLower debt is a constructive balance-sheet change that can reduce financing pressure and improve financial flexibility. Although equity remains negative, the reduction may moderate obligations and create a somewhat more manageable capital structure over the next several quarters.
Improved Cash BurnThe smaller operating cash outflow indicates some progress in controlling cash consumption, even though the company still burns cash. If maintained, this improvement could extend liquidity and reduce the pace at which external financing is required.
Focused Gene-Therapy PipelineA focused pipeline in severe retinal diseases gives GenSight a defined clinical and scientific direction. Progress in LUMEVOQ or GS030 could create durable strategic value by addressing serious unmet needs and building on specialized gene-therapy expertise.
Bears Say
Revenue CollapseA near-total revenue collapse demonstrates very limited commercial scale and makes the business highly dependent on future pipeline progress. Persistently weak revenue reduces internally generated funding capacity and increases uncertainty around the timing of a sustainable operating model.
Negative Shareholders’ EquityNegative equity is a significant solvency weakness because liabilities exceed the recorded asset base. This constrains financial flexibility, makes leverage harder to assess, and increases dependence on outside capital to sustain development and meet obligations.
Persistent LossesRecurring operating and net losses show that the business has not yet converted its research platform into sustainable earnings. Continued losses can consume capital, limit reinvestment flexibility, and keep profitability dependent on successful clinical and commercial execution.
GenSight Biologics SA News
0RIM FAQ
What was GenSight Biologics SA’s price range in the past 12 months?
GenSight Biologics SA lowest share price was €0.08 and its highest was €0.24 in the past 12 months.
What is GenSight Biologics SA’s market cap?
GenSight Biologics SA’s market cap is €19.64M.
When is GenSight Biologics SA’s upcoming earnings report date?
GenSight Biologics SA’s upcoming earnings report date is Mar 19, 2027 which is in 165 days.
How were GenSight Biologics SA’s earnings last quarter?
GenSight Biologics SA released its earnings results on Sep 29, 2026. The company reported -€0.05 earnings per share for the quarter.
Is GenSight Biologics SA overvalued?
According to Wall Street analysts GenSight Biologics SA’s price is currently same.
Does GenSight Biologics SA pay dividends?
GenSight Biologics SA does not currently pay dividends.
What is GenSight Biologics SA’s EPS estimate?
GenSight Biologics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GenSight Biologics SA have?
GenSight Biologics SA has 235,044,330 shares outstanding.
What happened to GenSight Biologics SA’s price movement after its last earnings report?
GenSight Biologics SA reported an EPS of -€0.05 in its last earnings report. Following the earnings report the stock price went down -12.281%.
Which hedge fund is a major shareholder of GenSight Biologics SA?
Currently, no hedge funds are holding shares in GB:0RIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GenSight Biologics SA
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
0RIM Stock 12 Month Forecast
Average Price Target
€0.08
▲(0.00% Upside)